Aclaris Therapeutics (ACRS) Projected to Announce Earnings on Thursday

Aclaris Therapeutics (NASDAQ:ACRS) is anticipated to issue its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect Aclaris Therapeutics to post earnings of ($0.16) per share and revenue of $1.3830 million for the quarter. Investors can find conference call details on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, August 6, 2026 at 12:30 PM ET.

Aclaris Therapeutics (NASDAQ:ACRS) last released its quarterly earnings results on Thursday, May 7th. The biotechnology company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.01. The company had revenue of $2.00 million for the quarter, compared to analysts’ expectations of $1.32 million. Aclaris Therapeutics had a negative return on equity of 55.89% and a negative net margin of 832.58%. On average, analysts expect Aclaris Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Aclaris Therapeutics Trading Down 3.9%

Shares of NASDAQ ACRS opened at $5.12 on Thursday. The stock has a 50 day simple moving average of $4.96 and a 200-day simple moving average of $4.18. The company has a market cap of $715.06 million, a PE ratio of -9.14 and a beta of 0.76. Aclaris Therapeutics has a 12-month low of $1.46 and a 12-month high of $5.88.

Analyst Ratings Changes

Several analysts recently commented on ACRS shares. Piper Sandler raised their target price on Aclaris Therapeutics from $7.00 to $11.00 and gave the company an “overweight” rating in a research report on Tuesday, May 5th. Oppenheimer started coverage on Aclaris Therapeutics in a research report on Thursday, April 16th. They set an “outperform” rating and a $10.00 price target for the company. Lifesci Capital initiated coverage on Aclaris Therapeutics in a research note on Tuesday, June 2nd. They issued an “outperform” rating and a $13.00 price target for the company. Guggenheim initiated coverage on Aclaris Therapeutics in a report on Tuesday, May 5th. They set a “buy” rating and a $12.00 price target on the stock. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Aclaris Therapeutics in a research note on Wednesday, June 24th. Three equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Buy” and an average price target of $11.50.

Institutional Trading of Aclaris Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. XTX Topco Ltd boosted its holdings in Aclaris Therapeutics by 76.6% during the fourth quarter. XTX Topco Ltd now owns 112,912 shares of the biotechnology company’s stock worth $340,000 after buying an additional 48,987 shares in the last quarter. Wells Fargo & Company MN increased its holdings in shares of Aclaris Therapeutics by 53.5% in the fourth quarter. Wells Fargo & Company MN now owns 104,465 shares of the biotechnology company’s stock valued at $314,000 after buying an additional 36,426 shares in the last quarter. Quadrature Capital Ltd increased its holdings in shares of Aclaris Therapeutics by 82.8% in the fourth quarter. Quadrature Capital Ltd now owns 57,670 shares of the biotechnology company’s stock valued at $174,000 after buying an additional 26,117 shares in the last quarter. Rhumbline Advisers lifted its position in shares of Aclaris Therapeutics by 7.4% during the 3rd quarter. Rhumbline Advisers now owns 91,236 shares of the biotechnology company’s stock valued at $173,000 after acquiring an additional 6,271 shares during the last quarter. Finally, Man Group plc acquired a new stake in shares of Aclaris Therapeutics during the 4th quarter valued at $128,000. 98.34% of the stock is currently owned by institutional investors.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc (NASDAQ:ACRS) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing novel small‐molecule therapies for dermatologic diseases and related rare disorders. The company’s pipeline includes several product candidates designed to address chronic inflammatory skin conditions and non‐melanoma skin lesions. Lead programs include ATI‐50002, a topical agent in late‐stage development for molluscum contagiosum removal; ATI‐50003 for common wart resolution; ATI‐1501, an oral JAK1/2 inhibitor targeting pruritic disorders; and ATI‐450, an oral MK2 inhibitor for inflammatory indications.

Founded in 2016 and headquartered in Malvern, Pennsylvania, Aclaris leverages proprietary chemistry platforms and translational research capabilities to advance multiple clinical and preclinical candidates.